Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury

NCT06096415 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Traumatic Brain Injury
Cerebral Edema

Interventions

DRUG: ABX-101 1mg
DRUG: ABX-101 2mg

Sponsor

Abalonex, LLC